COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Testosterone cipionate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms COMBAT-CRPC
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 12 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 19 Jun 2018 New trial record